Allison Bratzel
Stock Analyst at Piper Sandler
(4.58)
# 180
Out of 5,056 analysts
48
Total ratings
65.79%
Success rate
19.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGTX MeiraGTx Holdings | Maintains: Overweight | $28 → $30 | $7.75 | +287.10% | 1 | Nov 11, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $820 → $930 | $918.53 | +1.25% | 15 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $26 → $35 | $36.00 | -2.78% | 3 | Nov 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $70 → $77 | $74.50 | +3.36% | 3 | Nov 4, 2025 | |
| INCY Incyte | Maintains: Overweight | $82 → $102 | $103.89 | -1.82% | 3 | Nov 4, 2025 | |
| IOBT IO Biotech | Maintains: Overweight | $10 → $3 | $0.83 | +263.64% | 1 | Oct 22, 2025 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $52 → $51 | $39.81 | +28.12% | 4 | Sep 24, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $70 → $112 | $113.83 | -1.61% | 1 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $8.74 | +151.72% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $16.04 | +105.74% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $115 | $32.83 | +250.29% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $6 | $1.65 | +263.64% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $6.88 | +277.91% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $23 | $46.22 | -50.24% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $20.52 | +7.21% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $1.20 | +233.33% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $4.47 | +347.43% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.66 | +446.45% | 1 | Oct 13, 2023 |
MeiraGTx Holdings
Nov 11, 2025
Maintains: Overweight
Price Target: $28 → $30
Current: $7.75
Upside: +287.10%
argenx SE
Nov 4, 2025
Maintains: Overweight
Price Target: $820 → $930
Current: $918.53
Upside: +1.25%
Travere Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $26 → $35
Current: $36.00
Upside: -2.78%
Ionis Pharmaceuticals
Nov 4, 2025
Maintains: Overweight
Price Target: $70 → $77
Current: $74.50
Upside: +3.36%
Incyte
Nov 4, 2025
Maintains: Overweight
Price Target: $82 → $102
Current: $103.89
Upside: -1.82%
IO Biotech
Oct 22, 2025
Maintains: Overweight
Price Target: $10 → $3
Current: $0.83
Upside: +263.64%
Scholar Rock Holding
Sep 24, 2025
Maintains: Overweight
Price Target: $52 → $51
Current: $39.81
Upside: +28.12%
ABIVAX Société Anonyme
Jul 29, 2025
Maintains: Overweight
Price Target: $70 → $112
Current: $113.83
Upside: -1.61%
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $8.74
Upside: +151.72%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $16.04
Upside: +105.74%
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $32.83
Upside: +250.29%
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $1.65
Upside: +263.64%
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $6.88
Upside: +277.91%
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $46.22
Upside: -50.24%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $20.52
Upside: +7.21%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $1.20
Upside: +233.33%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.47
Upside: +347.43%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.66
Upside: +446.45%